FDA.reportPublic FDA data

Vyndamax 61 MG Oral Capsule

RxCUI
2168540
RxNorm name
Vyndamax 61 MG Oral Capsule
Display name
Vyndamax 61 MG Oral Capsule
Full name
Vyndamax 61 MG Oral Capsule
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:38:49

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
VyndaqelTAFAMIDIS MEGLUMINEPfizer Laboratories Div Pfizer Inc1b4121ee-a733-4456-a917-be26034778392026-05-12Adverse reactionsExact identifier
rxcui: 2168540

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
1b4121ee-a733-4456-a917-be2603477839Vyndamax 61 MG Oral Capsule [PSN] · tafamidis 61 MG Oral Capsule [Vyndamax] [SBD] · Vyndamax 61 MG Oral Capsule [SY]315These highlights do not include all the information needed to use VYNDAQEL and VYNDAMAX safely and effectively. See full prescribing information for VYNDAQEL and VYNDAMAX. VYNDAQEL ® (tafamidis meglumine) capsules, for oral administration Initial U.S. Approval: 2019 VYNDAMAX™ (tafamidis) capsules, for oral administration Initial U.S. Approval: 201920260512